<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04740866</url>
  </required_header>
  <id_info>
    <org_study_id>Bladder-03</org_study_id>
    <nct_id>NCT04740866</nct_id>
  </id_info>
  <brief_title>Adjuvant Radiotherapy Versus Observation After Radical Cystectomy in High Risk Urothelial Bladder Cancer</brief_title>
  <official_title>Prospective Randomized Trial of Adjuvant Radiotherapy Versus Observation After Radical Cystectomy in High Risk Urothelial Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective randomized clinical trial in high risk urothelial bladder cancer to&#xD;
      compare adjuvant radiotherapy versus observation after radical cyctectomy. This is to clarify&#xD;
      the benefit of adjuvant radiotherapy while limiting gastrointestinal toxicities for patients&#xD;
      with pathological high-risk bladder cancer through assessing locoregional control (LRC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is prospective randomized trial in high risk urothelial bladder cancer that includes 2&#xD;
      arms. The randomization will be done by permuted block method to 2 equal comparable groups.&#xD;
      The total number of subjects will be 50 in each arm (Total=100 subjects).&#xD;
&#xD;
      This study include patients who may receive neoadjuvant chemotherapy [Gemcitabine+Cisplatin])&#xD;
      or not.&#xD;
&#xD;
      Arm (1) in this study (N=50) will received irradiation of both the bladder tumor bed and&#xD;
      pelvic lymph nodes using IMRT technique. For Arm (2) (N=50) will undergo observation&#xD;
      following radical cystectomy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local Control</measure>
    <time_frame>Two year</time_frame>
    <description>2-year local-regional control rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>Two year</time_frame>
    <description>2-year disease free survival rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>High-Risk Cancer</condition>
  <condition>Urothelial Carcinoma Bladder</condition>
  <arm_group>
    <arm_group_label>Adjuvant Radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Irradiation of both the bladder tumor bed and pelvic lymph nodes using Intensity-Modulated Radiation-Therapy [IMRT] technique.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation after radical Cystectomy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>observation following radical cystectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Adjuvant Radiotherapy</intervention_name>
    <description>Irradiation of both the bladder tumor bed and pelvic lymph nodes using Intensity-Modulated Radiation-Therapy (IMRT) technique. ([50Gy in 25 fractions conventional fractionation including tumor bed &amp; pelvic lymph nodes]</description>
    <arm_group_label>Adjuvant Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patient with muscle-invasive urothelial cancer, who received neoadjuvant chemotherapy&#xD;
        followed by radical cystectomy and urinary diversion with negative safety margin and&#xD;
        belongs to one or more of the categories:&#xD;
&#xD;
          -  â‰¥ 18 years old.&#xD;
&#xD;
          -  PT3 or PT4a tumors.&#xD;
&#xD;
          -  Grade 3 urothelial cancer.&#xD;
&#xD;
          -  Positive infiltration of the dissected pelvic lymph nodes.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Residual tumors upon cystectomy.&#xD;
&#xD;
          -  Previous pelvic irradiation.&#xD;
&#xD;
          -  Non-urothelial bladder tumors.&#xD;
&#xD;
          -  WHO performance status above 2.&#xD;
&#xD;
          -  Any psychological, familial, sociological or geographical condition that hamper&#xD;
             compliance with the study and/ or follow up schedule.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Zaghloul, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>mszagh@yahoo.com</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed Zaghloul, MD</last_name>
    <phone>(20)-01001720664</phone>
    <email>mszagh@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Institute-Cairo University</name>
      <address>
        <city>Cairo</city>
        <zip>11465</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Zaghloul, MD</last_name>
      <phone>(20)01001720664</phone>
      <email>mszagh@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Mohamed Zaghloul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>Zaghloul MS, Awwad HK, Akoush HH, Omar S, Soliman O, el Attar I. Postoperative radiotherapy of carcinoma in bilharzial bladder: improved disease free survival through improving local control. Int J Radiat Oncol Biol Phys. 1992;23(3):511-7.</citation>
    <PMID>1612951</PMID>
  </results_reference>
  <results_reference>
    <citation>Zaghloul MS, Christodouleas JP, Smith A, Abdallah A, William H, Khaled HM, Hwang WT, Baumann BC. Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy: A Randomized Phase 2 Trial. JAMA Surg. 2018 Jan 17;153(1):e174591. doi: 10.1001/jamasurg.2017.4591. Epub 2018 Jan 17.</citation>
    <PMID>29188298</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 2, 2021</study_first_submitted>
  <study_first_submitted_qc>February 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Mohamed s. Zaghloul</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Adjuvant Radiotherapy</keyword>
  <keyword>Neoadjuvant chemotherapy</keyword>
  <keyword>Radical Cystectomy</keyword>
  <keyword>high risk Urothelial Carcinoma Bladder</keyword>
  <keyword>Local Control</keyword>
  <keyword>Disease Free Survival (DFS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

